TYRA
NASDAQTyra Biosciences Inc.
Price$18.57-0.19 (-0.99%)
01:30 PM07:45 PM
News · 26 weeks51-94%
2026-04-192026-10-11
Mix2390d
- SEC Filings8(35%)
- Other7(30%)
- Insider5(22%)
- Earnings3(13%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)
- INSIDERPresident and CEO Harris Todd was granted 864 shares, increasing direct ownership by 0.06% to 1,438,495 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERVice President, Finance (PAO) Rueb Yuliya was granted 2,925 shares, increasing direct ownership by 35% to 11,258 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERChief Financial Officer Fuhrman Alan was granted 951 shares, increasing direct ownership by 3% to 37,115 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.SCHEDULE 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form 424B5 filed by Tyra Biosciences Inc.424B5 - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- PRTyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsCARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22.029 per share, which equals the offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. All o
- SECSEC Form FWP filed by Tyra Biosciences Inc.FWP - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form S-3ASR filed by Tyra Biosciences Inc.S-3ASR - Tyra Biosciences, Inc. (0001863127) (Filer)
- INSIDERDirector Verjee Rehan bought $20,000 worth of shares (972 units at $20.58) (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- PRTyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with DabogratinibTYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBCFavorable safety and tolerability results support chronic dosing potentialNo clinically significant hyperphosphatemia, nail toxicity or ocular toxicity; low frequency of transaminase TEAEs (<10%); Grade 3 treatment-related AEs in fewer than 5% of patients (none at 60 mg QD)79% ORR and 64% best overall response CR rate with 60 mg QD in combined single and multiple marker lesion patients (n=14), with 100% ORR and 75% best overall response CR rate with 60 mg QD in single marker lesion patients (n=8), supporting planned adjuvant Phase 3 strategyFirst patient treated in Phase 2 SURF303 study
- PRTyra Biosciences to Present at the Cantor Global Healthcare ConferenceCARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference:Cantor Global Healthcare Conference 2026Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ETLocation: New York, NYA live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.Ab
- PRTyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).Conference Call and Webcast InformationTYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webca
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form 424B5 filed by Tyra Biosciences Inc.424B5 - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECSEC Form 10-Q filed by Tyra Biosciences Inc.10-Q - Tyra Biosciences, Inc. (0001863127) (Filer)
- PRTyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 -- Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy -- Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 -CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today
- SECTyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECSEC Form 144 filed by Tyra Biosciences Inc.144 - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
TYRA FAQ
7 questionsWhat does Tyra Biosciences Inc. do?
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad...Where does TYRA stock trade?
Tyra Biosciences Inc. (TYRA) is listed on NASDAQ.What sector and industry is TYRA in?
Tyra Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tyra Biosciences Inc. go public?
Tyra Biosciences Inc. (TYRA) completed its IPO in 2021.What are analysts saying about TYRA?
Tyra Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-05-19. Recent price targets range from $3300.00 to $3500.00.What companies are similar to TYRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TYRA side-by-side with any of them on Quantisnow.How can I track TYRA on Quantisnow?
Quantisnow aggregates Tyra Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TYRA to receive live email and push alerts on every new disclosure.